Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

NCT02882282 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Oral Cavity Carcinoma
Oral Intraepithelial Neoplasia

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Patient Observation
BIOLOGICAL: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]